The results confirmed that patients with low ratios of Sp1/NR2E3, β‐catenin/NR2E3, and p300/NR2E3 due to high NR2E3 levels had significantly more associated with favorable clinical outcomes, suggesting that high NR2E3 levels may play a suppressive role in the Sp1‐, β‐catenin‐, or p300‐mediated HCC development (Figure 7D). This evidence concerns the gene NR2E3 and hepatocellular carcinoma.